@Davisite with Domissini being on the authors list is it possible that he has information to present at the conference or would that have had to be included in the abstract? If he does have new information/data I would assume that would impact the release of the new strategy?
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-70
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
